Results Compared with placebo, reductions in HbA1c with dapagliflozin were 0.6%, 0.5%,
and 0.3%, respectively, for each consecutive lower eGFR subgroup (P value interaction< …

Background Patients with chronic kidney disease have a high risk of adverse kidney and
cardiovascular outcomes. The effect of dapagliflozin in patients with chronic kidney disease …

Background: Dapagliflozin reduces the risk of end-stage renal disease in patients with
chronic kidney disease. We examined the relative risk of cardiovascular and renal events in …

Background The DAPA‐CKD (Dapagliflozin and Prevention of Adverse Outcomes in
Chronic Kidney Disease) trial (NCT03036150) demonstrated that dapagliflozin reduced the …

Aim To evaluate the changes in renal endpoints in type 2 diabetes patients treated with
dapagliflozin versus other glucose‐lowering medications in routine clinical practice …

OBJECTIVE The Dapagliflozin and Prevention of Adverse outcomes in Chronic Kidney
Disease (DAPA-CKD) study demonstrated risk reduction for kidney and cardiovascular …

Aims Dapagliflozin is a selective inhibitor of sodium glucose co‐transporter 2 (SGLT2). This
study assessed the efficacy and safety of dapagliflozin 10 mg vs placebo in patients with …

Abstract Background The Dapagliflozin and Prevention of Adverse outcomes in Chronic
Kidney Disease (DAPA-CKD; NCT03036150) trial was designed to assess the effect of the …

Aims To characterize the effect of dapagliflozin on albuminuria and estimated glomerular
filtration rate (eGFR) and to determine whether effects on albuminuria were mediated …

Background In the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney
Disease (DAPA-CKD) randomized, placebo-controlled trial, the sodium-glucose …